Medical Supply Chain Resiliency Act

The Medical Supply Chain Resiliency Act, also known as Bill 118 s 2115, is a piece of legislation introduced in the US Congress with the aim of strengthening the country's medical supply chain. The bill seeks to address vulnerabilities in the supply chain that were exposed during the COVID-19 pandemic, such as shortages of personal protective equipment (PPE) and other essential medical supplies.

Key provisions of the bill include:

1. Establishing a task force to assess the current state of the medical supply chain and identify areas for improvement. 2. Developing a national strategy for ensuring the resiliency of the medical supply chain, including measures to increase domestic production of critical supplies. 3. Providing funding for research and development of new technologies and processes to enhance the efficiency and reliability of the supply chain. 4. Strengthening coordination and communication between federal, state, and local agencies, as well as private sector partners, to ensure a more coordinated response to future supply chain disruptions. Overall, the Medical Supply Chain Resiliency Act aims to ensure that the United States is better prepared to respond to future public health emergencies by shoring up the resilience of the medical supply chain. The bill has garnered bipartisan support in Congress and is seen as a critical step towards safeguarding the nation's healthcare system.